Podcasts about Novavax

In his weekly clinical update, Dr. Griffin with Vincent Racaniello debate the changes in FDA vaccine approval policy especially how it is applied to COVID-19 vaccines and restricts vaccine availability/usage and Novavax's vaccine, mpox on surfaces and in the air, “bird flu”, the ongoing measles outbreak globally before Dr. Griffin reviews recent statistics on RSV, benefits of vaccination for infants, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, the high number of childhood deaths during this “flu” season, the May 22 VRBPAC COVID-19 vaccine meeting, where to find PEMGARDA, prolonged steroid and antibiotic therapies, provides information for Columbia University Irving Medical Center's long COVID treatment center, where to go for answers to your long COVID questions, cognitive impairment in long COVID and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode FDA to issue new vaccine approval guidance amid questions over coronavirus shots (Washington Post) FDA vaccine committee meeting(Reuters) Evidence-based approach to COVID-19 vaccination (NEJM) FDA CBER townhall: new COVID019 vaccination approval mechanism (YouTube) FDA poised to restrict access to COVID vaccines, our own Dr. Griffin is cited! (NY Times) Novavax approval letter (FDA) We giveth and taketh away: Novavax approved but restricted use (AP News) FDA approves Novavax COVID vaccine with stricter new conditions (NY Times) History behind public health falsehoods– vaccine and autism (NPR) Making vaccines less accessible-RFK Jr making MAHA! (PBS News Hour) Kenneday says DO NOT to take medical advice from him, the HHS secretary…hummmm (NY Times) Staying up to date with COVID-19 vaccines (CDC: COVID-19) How science lost America's trust and surrendered health policy to skeptics (WSJ) HHS stops recommendation of COVID-19 shots for children and pregnant women (Reuters) No more routine COVID-19 vaccines for children and pregnant women (WSJ) House to investigate Pfizer for allegedly delaying COVID-19 vaccines (Reuters) Statement on the antigen composition of COVID-19 vaccines (WHO) WHO advisers say current strains OK for COVID vaccine production (CIDRAP) We can't remain indifferent to suffering: Catholic Church now champions HPV vaccination (DailyNation) Air and surface sampling for mpox in UK (Eurosurveillance) Researchers report mpox DNA, live virus on surfaces and in air from patients' rooms(CIDRAP) USDA reported H5N1 bird flu detection in wild birds (CDC: Avian Influenza) USDA reported H5N1 in poultry (CDC: Avian Influenza) HPAI Confirmed Cases in Livestock(USDA Animal and Plant Health Inspections Service) H5 bird flu: current situation (CDC: Avian Influenza) Bird flu (CDC: Avian Influenza) Measles cases and outbreaks (CDC Rubeola) Measles and rubella weekly monitoring report: (Government of Canada) Measles vaccine recommendations from NYP (jpg)  Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola) Measles vaccine (CDC Measles (Rubeola) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) FDA-CDC-DOD: 2025-2046 influenza vaccine composition (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States (CDC: COVID-19) COVID-19 vaccine VRBPAC May 22 (FDA) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC) Managing healthcare staffing shortages (CDC) Steroids,dexamethasone at the right time (OFID) The clinical impact of prolonged steroid therapy in severe COVID-19 patients (BMC Pulmonary Medicine) Anticoagulation guidelines (hematology.org) Antibiotic Treatment in Patients Hospitalized for Nonsevere COVID-19 (JAMA Network Open) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Self-reported health, neuropsychological tests and biomarkers in fully recovered COVID-19 patients vs patients with post-COVID cognitivesymptoms (PLoS One) Vortioxetine for Cognitive Impairment in Major Depressive Disorder During Post-COVID Syndrome (Journal of Clincial Psychiatrist) Reaching out to US house representative Letters read on TWiV 1220 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider the limited label that Novavax received for its new COVID-19 vaccine Nuvaxovid, the impact of the new COVID-19 vaccine development policy announced by the US Food and Drug Administration and additional upcoming indicators of the evolving policy. More On These Topics From The Pink Sheet Novavax's COVID-19 Vaccine Label Narrowed After Political Officials Intervened: https://insights.citeline.com/pink-sheet/vaccines/novavaxs-covid-19-vaccine-label-narrowed-after-political-officials-intervened-56OPC7DJ6NCXFLQYGE27SVTEH4/ Legal, Process Problems May Plague New US FDA COVID-19 Vaccine Policy: https://insights.citeline.com/pink-sheet/vaccines/legal-process-problems-may-plague-new-us-fda-covid-19-vaccine-policy-HAUDHEREXZCA5DAZ47HZ6L544U/ Observational, Retrospective Trials Could Retest Vaccines, HHS' Kennedy Says: https://insights.citeline.com/pink-sheet/vaccines/observational-retrospective-trials-could-retest-vaccines-hhs-kennedy-says-BOFKDMMHGVDNXKXMFEILOXAH4E/ US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems: https://insights.citeline.com/pink-sheet/vaccines/us-fda-covid-19-booster-strategy-may-not-be-as-controversial-as-it-seems-ZEAHMHE5LJB6HLBT2WRZW4L3AY/ US FDA Punts On New COVID-19 Framework's Impact On Fall Shots: https://insights.citeline.com/pink-sheet/product-reviews/us-advisory-committees/us-fda-punts-on-new-covid-19-frameworks-impact-on-fall-shots-QSB6OPEB4ZCEFLS36JG3Y7XSPE/

Pfizer stole the headlines this week with a pact worth up to $6 billion with Chinese biotech 3SBio for a PD-1/VEGF candidate just three months after inking a clinical trials collab for a similar drug with Summit Therapeutics. It's the largest Chinese licensing deal in recent memory, as pharmas continue to turn to the country to fill their pipelines.  Also on Tuesday, the Department of Health and Human Services offered a smidge more detail on President Donald Trump's Most Favored Nation executive order. A press release explained that drug prices will be tied to the lowest price in certain countries with a GDP at least 60% that of the U.S. and that the effort will focus on branded drugs.   Over at the FDA, the strategy around COVID-19 vaccines is evolving. According to an editorial published in the New England Journal of Medicine Tuesday by FDA Commissioner Marty Makary and CBER director Vinay Prasad, future COVID-19 approvals will focus on adults over 65 and high-risk individuals six months to 64 years old—a strategy they say will better align the U.S. with other high-income nations. This is also in sync with the Novavax approval, which came in Friday after a few delays.   Meanwhile, the FDA's Oncologic Drugs Advisory Committee (ODAC) is currently in the midst of a two-day meeting, but acquiring the necessary expertise was “absolute chaos,” according to an agency insider who spoke with BioSpace. This is partly due to the decimation of an FDA office that includes staff responsible for screening scientific and therapeutic area experts for conflicts of interest.  Going back to last week—which seems like a year ago at this point—we were somewhat shocked to learn that the CEO of one of the world's most valuable pharma companies is on his way out. Friday morning, Novo Nordisk announced that CEO Lars Fruergaard Jørgensen will be leaving the company after eight years at the helm. After peaking last June at about $155 apiece, the obesity leader's shares are currently worth just $68. Novo said the decision for Jorgensen to leave was mutual, but Jorgensen was not made available to speak on a call following the announcement.  Finally, a couple of milestones are worth noting: First, the Alzheimer's space got a big win on Friday when the FDA approved the first blood-based test for the disease—news that could be a boon to Eli Lilly's Kisunla and Biogen & Eisai's Leqembi. And second, a nine-month-old boy named KJ with a disease called CPS1 deficiency that affects just 1 in 1.3 million U.S. babies was treated with a single-use CRISPR treatment created just for him. It's an incredible story that highlights just how far gene editing has come, but it also highlights a rare disease crisis, with these sorts of ultra- and nanorare diseases lacking the necessary financial incentive to motivate biopharma's focus.   

On this week's episode, Grace Colón, Josh Schimmer, Sam Fazeli, Tess Cameron, Eric Schmidt, and Yaron Werber kick off with a discussion on recent policy moves including the appointment of Vinay Prasad as the director of the FDA's CBER division and nomination of Casey Means for U.S. Surgeon General, noting the impact on the XBI and uncertainty around vaccine gene therapy approvals. The group pondered what kind of regulator Prasad may be, predicting a stricter approach than his predecessor, Peter Marks. The conversation covered the shifting dynamics in vaccine approvals under the new FDA leadership, highlighting that delays like Novavax's flu combo signal heightened scrutiny, with mRNA follow-ons likely to pass under stricter labels, while new vaccines face raised efficacy bars. On the policy front, Trump's proposed “Most Favored Nation” drug pricing strategy raises alarms over a potential trillion-dollar hit to innovation and unintended consequences for U.S. drug prices. The conversation shifts to early data on Genocury's in vivo CAR-T, PTC's mixed Huntington's disease results, and Krystal's gene therapy for neuropathic keratitis. The episode concludes with a roundup of Q1 earnings results. *This episode aired on May 9, 2025.

Ohne Aktien-Zugang ist's schwer? Starte jetzt bei unserem Partner Scalable Capital. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Regeneron kauft 23andMe. Trump pusht 30-jährige Zinsen auf 5%. Trump mag die Kombo von Apple & Alibaba nicht. Xiaomi macht eigene Chips. NVIDIA ist offen für fremde Chips. Novavax darf endlich impfen. Ryanair-CEO will die 100 Millionen Bonus knacken. Wieso betreibt Ticketmaster eigene Konzerthallen? Das Flywheel von Live Nation (WKN: A0H0VZ) ist die Antwort. Atomkraft erlebt grade ein Revival. Südkorea ist der vielleicht größte Profiteur. Konkret: Korea Electric (WKN: 893161) und Doosan Škoda Power (WKN: A410GL). Diesen Podcast vom 20.05.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

IVF Clinic Bombing and Pro-Mortalism Ideology (00:02:09 - 00:09:27)Guy Edward Bartkus bombed a Palm Springs IVF clinic, killing himself and injuring five, motivated by pro-mortalism (life causes suffering, death is liberation). His manifesto, hosted on promortalism.com, rails against pro-lifers and life itself, reflecting a nihilistic, anti-human philosophy rooted in online subcultures.Cultural Nihilism and Social Media's Role (00:13:03 - 00:24:28)The bomber's pro-mortalism reflects a broader cultural nihilism, influenced by ideas like Gaia theory (humans as a virus) and amplified by social media platforms. Reddit, TikTok, and Tumblr are criticized as hubs for pseudo-intellectualism, fostering anti-life ideologies among isolated individuals.Bible Engagement as a Positive Trend (00:24:28 - 00:31:02)A LifeWay survey shows 48% of Americans view the Bible as true (up from 36% in 2016), with rising Bible sales and reading. This suggests a growing rejection of secular humanism and a return to spiritual values amid cultural nihilism.Covid as a Scam (Music Man Analogy) (00:41:36 - 00:50:18)A Brownstone Institute article compares the Covid response to The Music Man, where fear (inflated death counts, PCR test misuse) enriched “snake oil salesmen” like Fauci. This mirrors historical fearmongering (9/11, Waco) to erode rights, with elites profiting from compliance.Trump's Tariffs Impact on Small Businesses (01:11:21 - 01:16:20)An NFIB survey shows Trump's unpredictable tariffs are reducing small business optimism (down to 95.8, below the 51-year average), creating market uncertainty akin to Covid-era disruption. Small businesses face tight margins, reduced hiring, and stalled investments, with tech sector impacts highlighted by YouTubers Louis Rossman and Gamers Nexus.DEA Corruption in Drug War (01:27:30 - 01:35:58)An AP article reveals Diego Marin, a Cali cartel figure, evaded capture with DEA complicity, bribing agents while building a $100M money-laundering empire. Compared to Whitey Bulger and Iran-Contra, it's framed as a problem-reaction-solution tactic to expand the police state.Mexican Navy Ship Crash (01:37:07 - 01:39:26)An NBC News report describes a Mexican Navy sailing ship crashing into the Brooklyn Bridge, killing two and injuring 22 due to a mechanical failure. The surreal event stunned New Yorkers, highlighting the unexpected nature of Mexico's sailing navy.CDC Covid Vaccine Recommendations (01:52:26 - 01:56:33)A Wall Street Journal article reports the Trump administration plans to drop routine Covid vaccine recommendations for pregnant women, teenagers, and children, led by HHS Secretary RFK Jr. The host criticizes the CDC's blanket recommendation (everyone 6 months and older) due to no long-term safety data, profit-driven motives, and harmful side effects, arguing the vaccine should be removed entirely.HHS Covid Vaccine Recommendations and Authority (02:05:33 - 02:13:16)Dr. Ruby critiques HHS's plan to stop recommending Covid vaccines for children and pregnant women as a red herring, given its authority over FDA, NIH, CMS, and CDC to demand immediate removal. She warns of deceptive terms like “considering” and questions state chemtrail bans, citing federal exemptions (Title 50, Prep Act) and global air circulation, suspecting controlled opposition.Novavax Approval Critique and Bird Flu (02:21:20 - 02:30:03)The FDA fully approved Novavax's Covid shot, marketed as non-mRNA but using synthetic spike proteins from moth cells, posing risks like myocarditis with no long-term studies. Dr. Ruby warns of off-label use and compares it to Pfizer/Moderna's rollout. She critiques bird flu as a fabricated threat, with chicken culling inflating egg prices and testing economic control, not addressing real disease.Vaccine Shedding and Industry Protections (02:16:43 - 02:51:36)Pfizer's investigator brochure admits Covid vaccine shedding via inhalation and skin contact, raising concerns about unknown contents affecting unvaccinated individuals. Dr. Ruby highlights the vaccine industry's Prep Act immunity, with government payouts in vaccine court, and Pfizer's 50% non-disclosure agreement, allowing undisclosed ingredients, akin to coercive contracts demanding country assets.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

Dr. Jane Ruby (DrJaneRuby.com) exposes HHS's deceptive plan to halt Covid vaccine recommendations for kids and pregnant women, despite its authority to enforce removal, and questions state chemtrail bans amid federal exemptions. Critiquing the FDA's approval of Novavax's risky Covid shot.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

IVF Clinic Bombing and Pro-Mortalism Ideology (00:02:09 - 00:09:27)Guy Edward Bartkus bombed a Palm Springs IVF clinic, killing himself and injuring five, motivated by pro-mortalism (life causes suffering, death is liberation). His manifesto, hosted on promortalism.com, rails against pro-lifers and life itself, reflecting a nihilistic, anti-human philosophy rooted in online subcultures.Cultural Nihilism and Social Media's Role (00:13:03 - 00:24:28)The bomber's pro-mortalism reflects a broader cultural nihilism, influenced by ideas like Gaia theory (humans as a virus) and amplified by social media platforms. Reddit, TikTok, and Tumblr are criticized as hubs for pseudo-intellectualism, fostering anti-life ideologies among isolated individuals.Bible Engagement as a Positive Trend (00:24:28 - 00:31:02)A LifeWay survey shows 48% of Americans view the Bible as true (up from 36% in 2016), with rising Bible sales and reading. This suggests a growing rejection of secular humanism and a return to spiritual values amid cultural nihilism.Covid as a Scam (Music Man Analogy) (00:41:36 - 00:50:18)A Brownstone Institute article compares the Covid response to The Music Man, where fear (inflated death counts, PCR test misuse) enriched “snake oil salesmen” like Fauci. This mirrors historical fearmongering (9/11, Waco) to erode rights, with elites profiting from compliance.Trump's Tariffs Impact on Small Businesses (01:11:21 - 01:16:20)An NFIB survey shows Trump's unpredictable tariffs are reducing small business optimism (down to 95.8, below the 51-year average), creating market uncertainty akin to Covid-era disruption. Small businesses face tight margins, reduced hiring, and stalled investments, with tech sector impacts highlighted by YouTubers Louis Rossman and Gamers Nexus.DEA Corruption in Drug War (01:27:30 - 01:35:58)An AP article reveals Diego Marin, a Cali cartel figure, evaded capture with DEA complicity, bribing agents while building a $100M money-laundering empire. Compared to Whitey Bulger and Iran-Contra, it's framed as a problem-reaction-solution tactic to expand the police state.Mexican Navy Ship Crash (01:37:07 - 01:39:26)An NBC News report describes a Mexican Navy sailing ship crashing into the Brooklyn Bridge, killing two and injuring 22 due to a mechanical failure. The surreal event stunned New Yorkers, highlighting the unexpected nature of Mexico's sailing navy.CDC Covid Vaccine Recommendations (01:52:26 - 01:56:33)A Wall Street Journal article reports the Trump administration plans to drop routine Covid vaccine recommendations for pregnant women, teenagers, and children, led by HHS Secretary RFK Jr. The host criticizes the CDC's blanket recommendation (everyone 6 months and older) due to no long-term safety data, profit-driven motives, and harmful side effects, arguing the vaccine should be removed entirely.HHS Covid Vaccine Recommendations and Authority (02:05:33 - 02:13:16)Dr. Ruby critiques HHS's plan to stop recommending Covid vaccines for children and pregnant women as a red herring, given its authority over FDA, NIH, CMS, and CDC to demand immediate removal. She warns of deceptive terms like “considering” and questions state chemtrail bans, citing federal exemptions (Title 50, Prep Act) and global air circulation, suspecting controlled opposition.Novavax Approval Critique and Bird Flu (02:21:20 - 02:30:03)The FDA fully approved Novavax's Covid shot, marketed as non-mRNA but using synthetic spike proteins from moth cells, posing risks like myocarditis with no long-term studies. Dr. Ruby warns of off-label use and compares it to Pfizer/Moderna's rollout. She critiques bird flu as a fabricated threat, with chicken culling inflating egg prices and testing economic control, not addressing real disease.Vaccine Shedding and Industry Protections (02:16:43 - 02:51:36)Pfizer's investigator brochure admits Covid vaccine shedding via inhalation and skin contact, raising concerns about unknown contents affecting unvaccinated individuals. Dr. Ruby highlights the vaccine industry's Prep Act immunity, with government payouts in vaccine court, and Pfizer's 50% non-disclosure agreement, allowing undisclosed ingredients, akin to coercive contracts demanding country assets.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Dr. Jane Ruby (DrJaneRuby.com) exposes HHS's deceptive plan to halt Covid vaccine recommendations for kids and pregnant women, despite its authority to enforce removal, and questions state chemtrail bans amid federal exemptions. Critiquing the FDA's approval of Novavax's risky Covid shot.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Send us a textThe FDA has granted full approval to Novavax's COVID-19 vaccine, providing an alternative to mRNA vaccines that works through a different mechanism using proteins and adjuvants. Despite being four years into the pandemic, COVID-19 remains a significant health concern, causing approximately 1 in 200 deaths in the US in 2025.• Novavax uses bioengineered spike proteins combined with an adjuvant rather than mRNA technology• FDA approved Novavax for all Americans over 65 and those 12-64 with at least one risk factor• Risk factors include conditions like asthma, diabetes, and obesity• Northeast Florida contributed 500 patients to the original Novavax clinical trials• Encore Research Group is currently enrolling participants for an oral COVID vaccine clinical trial• Participants in the oral vaccine trial will receive compensation for their timeFor more information about participating in the oral COVID vaccine study, visit EncoreDocs.com or call 904-730-0101.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Voor het eerst in ruim 100 jaar tijd krijgt Amerika moeilijk nieuws te verwerken van kredietbeoorelaar Moody's. Het mag zich namelijk niet meer tot de Triple-A-club rekenen. Volgens Moody's is de staatsschuld te hoog opgelopen, en is het geen gegeven meer dat de overheid z'n schulden afbetaalt. Maar wat ga jij daarvan merken? Financiënminister Scott Bessent noemt het de schuld van de vorige regering, die te veel heeft uitgegeven. Maar ondertussen is Donald Trump juist van plan om de belastingen te verlagen. Hoe lang kan Amerika nog door blijven gaan zonder de staatsschuld aan te pakken? En hoe kan het die schuld dan afbouwen? Ook dat hoor je in deze aflevering. Dan hebben we het ook over een ander historisch moment. De potscherven van de Brexit worden bij elkaar geveegd, en de EU en het VK doen een poging om die weer bij elkaar te lijmen. Onder druk van Trump's handelsoorlog en geopolitieke spanningen kwamen de twee machten bij elkaar. Conclusie: de Britten krijgen weer een soort light-versie van een EU-lidmaatschap. Verder hoor je over de nieuwe topman van JP Morgan Chase. Die is nog niet uitgekozen, maar heeft nu wel de kans om zich op de kaart te zetten. De beleggersdag van de grootste bank van de VS staat in het teken van de opvolger van Jamie Dimon, die al heeft aangegeven binnen nu en vijf jaar te stoppen. Wij vertellen je wie kans maken op die titel van machtigste bankier ter wereld, en wiens kans het grootste is. En we hebben een saillant detail over Just Eat Takeaway. De overname door Prosus wordt door verschillende aandeelhouders bekritiseerd. Maar ook Just Eat zelf was er niet meteen blij mee.See omnystudio.com/listener for privacy information.

Voor het eerst in ruim 100 jaar tijd krijgt Amerika moeilijk nieuws te verwerken van kredietbeoorelaar Moody's. Het mag zich namelijk niet meer tot de Triple-A-club rekenen. Volgens Moody's is de staatsschuld te hoog opgelopen, en is het geen gegeven meer dat de overheid z'n schulden afbetaalt. Maar wat ga jij daarvan merken? Financiënminister Scott Bessent noemt het de schuld van de vorige regering, die te veel heeft uitgegeven. Maar ondertussen is Donald Trump juist van plan om de belastingen te verlagen. Hoe lang kan Amerika nog door blijven gaan zonder de staatsschuld aan te pakken? En hoe kan het die schuld dan afbouwen? Ook dat hoor je in deze aflevering. Dan hebben we het ook over een ander historisch moment. De potscherven van de Brexit worden bij elkaar geveegd, en de EU en het VK doen een poging om die weer bij elkaar te lijmen. Onder druk van Trump's handelsoorlog en geopolitieke spanningen kwamen de twee machten bij elkaar. Conclusie: de Britten krijgen weer een soort light-versie van een EU-lidmaatschap. Verder hoor je over de nieuwe topman van JP Morgan Chase. Die is nog niet uitgekozen, maar heeft nu wel de kans om zich op de kaart te zetten. De beleggersdag van de grootste bank van de VS staat in het teken van de opvolger van Jamie Dimon, die al heeft aangegeven binnen nu en vijf jaar te stoppen. Wij vertellen je wie kans maken op die titel van machtigste bankier ter wereld, en wiens kans het grootste is. En we hebben een saillant detail over Just Eat Takeaway. De overname door Prosus wordt door verschillende aandeelhouders bekritiseerd. Maar ook Just Eat zelf was er niet meteen blij mee.See omnystudio.com/listener for privacy information.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Takeda's $30 billion investment in the U.S. is making headlines, along with their opposition to Trump's proposal on drug prices. The FDA's appointment of Vinay Prasad is stirring up mixed reactions within the industry. On another note, Lilly's legal victory against compounders, Novavax's growing sales, and Gilead's significant investment in U.S. manufacturing are all key developments. The FDA vaccine advisors are gearing up for a meeting to discuss COVID-19 updates, while Vor Bio is seeking an exit due to funding challenges. Biotech stocks took a hit following Prasad's appointment to lead CBER, highlighting the industry's current challenges including vaccine hesitancy and job market struggles.

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, Senior Editor Sue Sutter and Editor in Chief Nielsen Hobbs consider the impact of FDA Commissioner Martin Makary directing one of his assistants to take over the review of Novavax's COVID-19 vaccine (:40), as well as how states or courts could respond (19:19). They also discuss several announcements of missed user fee deadlines and whether FDA layoffs could have contributed (28:33). More On These Topics From The Pink Sheet Updated: Makary Backs New Novavax COVID-19 Trial, Political Officials Take Over Product Review: https://insights.citeline.com/pink-sheet/vaccines/political-official-pushing-novavax-to-conduct-covid-19-vaccine-postmarket-rct-BZTIWKSTK5G77BUQGGD3G2IOFY/ How States And Courts Could Insulate America From An Anti-Vaccine Executive Branch: https://insights.citeline.com/pink-sheet/vaccines/how-states-and-courts-could-insulate-america-from-an-anti-vaccine-executive-branch-DARDVWDMLVFCHM6DE75AJQHSBQ/ US FDA Commissioner's Office Plans Involvement In Many Approvals In Potential Major Change: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fda-commissioners-office-plans-involvement-in-many-approvals-in-potential-major-change-JFPWOQ2VF5D2JAFKXKGK54REZU/ US FDA Miss On Stealth's Elamipretide Boosts Signal Of Broader Delays Due To Staff Cuts: https://insights.citeline.com/pink-sheet/product-reviews/us-fda-miss-on-stealths-elamipretide-boosts-signal-of-broader-delays-due-to-staff-cuts-5ITZREGXX5H75ID6IL4Q2MHKBE/

Policy issues—particularly tariffs—loom large as Q1 2025 earnings season rolls on, with Pfizer , Novartis, AstraZeneca and many more all reporting this week. On Pfizer's call, CEO Albert Bourla called the Trump administration's national security concerns “legitimate,” but objected to the proposed tariffs in general. Meanwhile, Novartis CEO Vas Narasimhan brushed off the tariff risk but expressed concern over President Donald Trump's desire to bring back the ‘Most Favored Nations' rule.  Meanwhile, cancer conference season is in full swing, with the American Association for Cancer Research's annual event continuing in Chicago. Merck, GSK, Boehringer Ingelheim, Roche and others have presented highly anticipated data from some of their cornerstone cancer drugs and other candidates.  Turning to the latest news out of the FDA, newly minted Commissioner Marty Makary gave his first two big press interviews last week, making statements that both jibed with and contradicted recent reporting. And in the midst of the ongoing Novavax vaccine saga, many have raised concerns that the FDA could become politicized under the watch of HHS Secretary RFK Jr.  Finally, check out this week's BioPharm Executive stories, including a deep dive into the trend toward mining innovative therapies from China and BioSpace's annual report on pharma CEO-to-employee pay ratios. 

DAMION1White House blasts Amazon over tariff cost report: ‘Hostile and political act'The White House on Tuesday slammed Amazon for reportedly planning to display the cost of President Donald Trump's tariffs next to the total price of products on its site.“This is hostile and political act by Amazon,” White House press secretary Karoline Leavitt told reporters. “Why didn't Amazon do this when the Biden administration hiked inflation to the highest level in 40 years?” Leavitt asked.The Trump administration's aggressive swipe came in response to a report that Amazon will soon show consumers how much of an item's cost comes from tariffs. The amount added as a result of tariffs will be displayed right next to each product's total listed price, a person familiar with the plan told the news outlet.WHO DO YOU BLAME?CEO Andrew Jassy.He's the “boss.”Maybe he feels emasculated?Lowest overall batting average (.308)only 6% influence compared to his boss, Jeff Bezos (67%)Not paid like traditional CEOs (relying instead on his $275M in unvested equity) and the $38M that vested last year; so when he's hanging out withHis buddies like Target CEO Brian Cornell ($20M) eBay CEO Jamie Iannone ($22M) have the total summary compensation bragging rights. Not to mention the sad, unmanly CEO Pay Ratio which is listed as 43:1 for Jassy and 753:1 for the DEI-hating Cornell Jeffrey Preston Bezos (67%)I mean he's the actual boss, right?Executive Chair, founder, former CEO, superstar.Hangs out with people like Katy Perry, has a newspaper, sends penis rockets to nowhere, has pretend funds named after himself like the Bezos Earth Fund and the Bezos Day One FundBoard member and former Pepsi CEO Indra NooyiOr maybe this is a DEI problem? Amazon's Audit Committee is tasked with stuff like operational risks, and legal and regulatory matters. Indra chairs this committeeIndra is also involved with very woke-y/DEI-y:stuff like science (Trustee of Memorial Sloan Kettering Cancer Center)Stuff like math (Member of the Dean's Advisory Council at MIT's School of Engineering)Stuff like art (Trustee of the National Gallery of Art)And stuff like giving a shit about people, stakeholder-y capitalism stuff (Director of Partnership for Public Service, whose mission is to inspire a new generation of civil servants and to transform the way government works)Former President Joe BidenAmazon later clarified that the plan to show tariff surcharges was “never approved” and is “not going to happen.” Trump personally called Bezos on Tuesday morning to express his displeasure about the initial report that spurred the heated response from the White House.Trump world's Laura Loomer takes aim at a 'woke' Lockheed Martin and its $2 trillion F-35 programLaura Loomer, the far-right activist who has a direct line to President Donald Trump, criticized Lockheed Martin's F-35 program over the weekend, decrying the US defense giant as "woke" and lashing out against the expensive stealth aircraft.In a lengthy post on X, Loomer suggested Lockheed Martin is delivering F-35 Lightning II Joint Strike Fighters that "are simply not ready for combat.""The F-35 program, one of the most expensive weapons programs in history, is plagued by delays, defects, & downright incompetence," she wrote Saturday. She said the US Air Force is accepting jets that lack "functional" radar systems, without offering evidence.She also claimed that Lockheed is "increasingly obsessed with pushing a woke agenda." Like many other US defense contractors, Lockheed scrapped its diversity, equity, and inclusion programs in January after Trump returned to the White House.The $2 trillion F-35 program is an appealing target for activists and officials seeking to slash government spending, and it has a well-documented list of problems. The Pentagon's top weapons tester said earlier this year that the program had problems delivering functional software and had fallen behind schedule to test upgraded mission systems.WHO DO YOU BLAME?The 2025 Proxy Statement that mentions “diversity” five times!Of course all five of those instances were in the anti-woke/anti-DEI shareholder proposal introduced by the Bahnsen Family Trust.Not sure how this even made the proxy after Lockheed's anti-DEI move in January: “As we publicly stated following the issuance of President Trump's January 2025 Executive Order on DEI, we will not have goals or incentives based on demographic representation or Affirmative Action Plans. We are actively reviewing our workforce-related policies to ensure they are, and remain, compliant and aligned with the Executive Order and all related applicable legal precedent.”The three-headed white guy leadership group (53% influence)CEO/Chair James Taiclet (25%): $24M in payLead Independent Director and Nominating Committee chair Thomas J. Falk (13%)“Independent” since 2010David Burritt (15%)Longest-tenured director (2008-)Busy beaver: two committees (Audit and Pay); CEO of US. SteelSince this is a woke/DEI issue: the black guy:Nevermind, there are no black people on this boardA woman? It would have to be Debra Reed-Klages (17%)While she has no leadership roles she does sit on the board of Caterpillar, which also removed its DEI policies. What, what?Investors. They should have been holding Lockheed accountable, right?According to MSCI data, average support since 2015 is 95%; no director has even received less than 92% since 2017Say on Pay support is routinely over 90%Starbucks union rejects company's recent offer of at least 2% annual pay raiseStarbucks union delegates involved in contract bargaining voted to reject the coffee chain's latest proposal that guaranteed annual raises of at least 2%, Workers United said. Out of the 490 baristas representing the company's more than 550 unionized U.S. stores, 81% rejected the proposal, which did not offer any changes to economic benefits such as healthcare or any immediate pay hike.WHO DO YOU BLAME?The union, for being greedy.The company pays its baristas about $19 an hour on average currently. That's $39,520 before taxes. A 2% raise would result in an increase of $790.40!InvestorsAverage director support of 96% over past 2 yearsEven 86% support for new CEO Brian Niccol's $96M, including $5M in funny munny cashAnd a devilishly perverse CEO pay ratio of 6,666 to 1.Not to mention Use of Starbucks aircraft for travel between city of primary residence and Starbucks headquarters AND up to $250,000 in personal non-commuting travel per yearWhich brings us to the CEO, Brian Niccol, a guy so wonderful that they scrapped the independent chair nonsense and gave him both titles: CEO and ChairLead Independent Director and Nominating Committee chair Jørgen Vig KnudstorpAveraged over 10% votes against over the past 3 AGMs: which is essentially an investor revolutionHis favorite drink–the Caramel Macchiato–is 250 calories with 33g of sugar: the American Heart Association recommends that women consume no more than 25 grams per dayMATT1Novavax appoints Charles Newton to board of directorsChuck Newton has a background from BofA Merrill, Credit Suisse, Morgan Stanley, and Lehman as an investment banker, and is now CFO at a pharma company. He got his education in business administration and “arts”.Who do we blame for the appointment of Chucky?John Jacobs, CEO and highest influence on the board at 23%New board chair and nom committee chair Margaret McGlynn, who will inherit retiring director James Young's 16% influence to become the most influential person on the board?Too much science?Actual knowledge of pharmaceutical science - Young's retirement means there are only 2 actual scientists left on the board of the 9 members - 6 have finance backgrounds, and 1 is a lawyer.DEI - while Novavax's SEC disclosure says that the 9 person board has 1 male with 2 or more races and 2 women, they actually didn't feel white ENOUGH so they added Charles Newton to have a 100% white board (because black people don't even get malaria, COVID, or flu)They actually claim to have 10 board members when they really have 9Investors - who actually hate this board and can't possibly like it more now?Classified board, last year the new board chair (promotion!) got 52% votes for, the PhD got 58% for, and the guy from the family foundation got 53% for - and yes, exactly 35% of the shares are owned by State Street, Vanguard, BlackRock, and Shah CapitalSam Altman says OpenAI will fix ChatGPT's ‘annoying' new personality as users complain the bot is sucking up to them“ChatGPT's new personality is so positive it's verging on sycophantic—and it's putting people off.”Who do we blame for AI being a big fat suckup?Sam Altman, for being a big fat Trump suckupSam Altman, for having an insipid tech bro personality desperately seeking the fame and attention of the earthSam Altman, for firing his non-suckup board membersSam Altman, for putting himself on the board and surrounding himself with board suckups

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The first quarter earnings calls of major pharmaceutical companies were dominated by uncertainty surrounding President Trump's tariffs. Merck took a $200 million hit due to the tariffs, while Roche believes it is well-positioned to weather the impact. Despite challenges, companies are preparing for potential impacts of the tariffs on their businesses. This uncertainty is also affecting M&A activity in the pharmaceutical industry. Wacker Biotech is positioning itself as a partner for advanced therapies, offering services for process development and production of PDNA and mRNA therapies. Novavax asserts that its COVID-19 shot is "approvable", Vanda criticizes the FDA for delays, and there are updates on investments in innovative therapies. The industry is also reshaping the women's health landscape with economic challenges and strategic investments. Overall, companies are navigating through challenges while striving to thrive in a changing biotech landscape.

In his weekly clinical update, Dr. Griffin with Vincent Racaniello rue about the continuation of the gutting of the American public health infrastructure, the continuing measles outbreak, an unreported outbreak of deadly E.coli human infections, meningococcal disease before Dr. Griffin reviews recent statistics on RSV, influenza and SARS-CoV-2 infections, the WasterwaterScan dashboard, ACIP recommended changes in guidelines for the RSV and COVID-19 vaccines, reactogenicity differences between Novavax and Pfizer COVID-19 vaccines, where to find PEMGARDA, provides information for Columbia University Irving Medical Center's long COVID treatment center, where to go for answers to your long COVID questions, long COVID interventions, effects of long COVID in children and adolescents and a list of ongoing clinical trials for long COVID treatment. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Making America Healthy Again-purging of administrators at HHS (Politico) Making America Healthy Again-purging of data (Politico) Deep cuts of the federal government (NY Times) Cutting NIH, CDC and HHS promotes chronic disease research(Washington Post) Political ideology and trust in scientists in the USA(Nature Human Behavior) US political conservatives have deep, unbudging suspicion of science, survey suggests(CIDRAP) A deadly E. coli outbreak hit 15 states, but the FDA chose not to publicize it(NBC News) Invasive meningococcal disease – Kingdom of Saudi Arabia(WHO) The essential guide to understanding the differences between hajj and umrah (Marhabahaji) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Measles booster? (Washington Post) How to stop an outbreak…….fire the experts (Washington Post) Measles cases and outbreaks (CDC Rubeola) Measles 159 in Texas…. (Texas Health and Human Services) 2025 Measles outbreak guidance (New Mexico Health) Measles and rubella weekly monitoring (Government of Canada) Measles vaccine recommendations from NYP (jpg) NAFMA: North American Free Measles agreement…..(NY Times) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Doctors' talk measles (YouTube) Measles (CDC: Measles Rubeola) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Respiratory virus activity levels (CDC Respiratory Illnesses) 200 children die from flu (CIDRAP) Weekly surveillance report: clift notes (CDC FluView) FDA-CDC-DOD: 2025-2046 influenza vaccine composition (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) ACIP votes to expand recommendation for Pfizer'sRSV vaccine Abrysvo® to include adults aged 50 to 59 at increased risk of disease (Pfizer) Respiratory syncytial virus and incidence of cardiovascular events: a nationwide self-controlled case series analysis (JACC Journals) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Comorbidities associated with different degrees of severity in children and young people hospitalized with acute COVID-19 (Pediatric Infectious Disease Journal) SHIELD-Utah study shows Novavax's COVID-19 vaccine induces lower reactogenicity symptoms compared to mRNA (Novavax) Interim clinical considerations for use of COVID-19 vaccines in the United States (CDC Vaccines & Immunizations) Novavax says its COVID vaccine produces fewer, milder reactions than Pfizer version(CIDRAP) US CDC advisers discuss narrower use of COVID-19 vaccines (Reuters) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Fusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC) Managing healthcare staffing shortages (CDC) Steroids, dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Kidney Function following COVID-19 in children and adolescents(JAMA Network Open) Cardiovascular post-acute sequelae of SARS-CoV-2 in children and adolescents: cohort study using electronic health records(Nature Communications) Great barrington declaration (gbdeclaration.org) Clinical trials: Effectiveness of transcranial direct current in patients with persistent COVID-19 with headaches and chronic pain. Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC) Acupuncture for post COVID-19 Condition (Long COVID) neuropsychiatric symptoms Pain relief with integrative medicine (prime)?: feasibility of acupuncture for long COVID Electro-acupuncture for long COVID neuropsychiatric symptoms Randomised study to investigate the effectiveness of acupuncture for the relief of long COIVD-19 related fatigue (ACU-COVID) Vagus stimulation in female long COVID patients.(Vagus) Stellate ganglion block with lidocaine for the treatment of COVID-19-induced parosmia (Stella) Therapeutic updates on long COVID: Where things stand 5 years later (ID Society) Reaching out to US house representative Letters read on TWiV 1210 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

In "Public Health Policy is Political," Chris Dall and Dr. Osterholm discuss the ongoing measles outbreak, the latest round of job cuts in the public health workforce, and new studies on long-COVID. Dr. Osterholm also reviews the latest vaccine news for Novavax, seasonal influenza, and H5N1. Studies: 1 in 7 US working-age adults report long COVID, with heaviest burden on the poor (CIDRAP) A Clearer Picture of Covid's Lasting Effects on the Body (NYT, paywall) MORE EPISODES       SUPPORT THIS PODCAST  

Hier geht es direkt zur neuen Ausgabe (15.04.25) https://www.heiko-thieme.club/2025/04/15/trotz-wundertuete-trump-panik-ist-keine-anlagestrategie-die-anleger-zwischen-geiz-und-gier-mit-der-3-3-strategie/ Trotz "Wundertüte Trump" - "Panik ist keine Anlagestrategie." Die Anleger zwischen "Geiz und Gier" - mit der 3/3-Strategie? "Panik ist keine Anlagestrategie." - ein Zitat von Peter Lynch. In den vergangenen 10 Tagen ist sehr viel an den Börsen passiert, nach Trumps "Liberation Day". Alle Clubmitglieder haben es ja miterlebt. Die Medien nannten es "Black Friday", dann kam der "Panik-Monday" und schließlich der "Turnaround Thursday". Wundertüte Trump - er bleibt unberechenbar und stellt an den weltweiten Märkten weiterhin ein Risiko dar. Zwar ist Trump hinsichtlich der Zölle ein wenig zurückgerudert, doch der bereits entstandene Schaden ist immens. Wie hoch wäre der Preis, wenn man Vertrauen verzollen müsste? In dieser Heiko-Thieme-Club-Ausgabe haben wir sehr viele Fragen und Aktien besprochen. Kaufen, verkaufen, halten: Microsoft, Novo Nordisk, Nike, BYD, diverse ETFs - Amundi Stoxx Europe 600, FTSE All World ETF, MSCI World All Country, Aixtron, Rheinmetall-Aktie, SMA Solar, Novavax, Siltronic …

TWiV reviews RFK Jr's odd comments on ‘single antigen' vaccines and his September deadline for understanding why autism has increased, dire wolf does not come back from the dead, oral norovirus vaccine tablet that induces mucosal immunity in older adults, and identification of broadly neutralizing human monoclonal antibodies against norovirus. Hosts: Vincent Racaniello, Alan Dove, Kathy Spindler, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV ASV 2025 RFK Jr. and Novavax (MSN) September deadline to understand autism rise (Reuters) Dire wolf not resurrected (Science) Oral norovirus vaccine tablet (Sci Transl Med) Broadly neutralizing norovirus monoclonal antibodies (Sci Transl Med) Letters read on TWiV 1209 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Brianne – New experiment updates classic experiment on how life on Earth started Kathy – APOD ISS meets Venus, Sign up for NASA ISS alerts, GoISS Watch Alan – Mason bees could replace honeybees as crop pollinators Vincent – Mystery of medieval manuscripts revealed by ancient DNA Listener Pick Sonrisa – GOT'EM Good! Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

In his weekly clinical update, Dr. Griffin and Vincent Racaniello lament about the continuing measles outbreak, whether or not the measles outbreak was predicted, the FACTS about vaccination, high pathogenic influenza, H5N1 contaminated raw pet food, children's deaths, before Dr. Griffin reviews recent statistics on RSV, influenza and SARS-CoV-2 infections and vaccination schedules and the efficacy of Moderna's seasonal mRNA vaccine, societal burden of COVID-19 and influenza, the FDA missed deadline for approving Novovax COVID vaccine, the WasterwaterScan dashboard, where to find PEMGARDA, provides information for Columbia University Irving Medical Center's long COVID treatment center, where to go for answers to your long COVID questions, long COVID interventions, and Canada's long COVID dashboard. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode CDC buried a measles forecast that stressed the need for vaccinations….TRANSPARENCY? (Politico) Measles cases and outbreaks (CDC Rubeola) Measles 159 in Texas…. (Texas Health and Human Services) 2025 Measles outbreak guidance (New Mexico Health) Measles and rubella weekly monitoring report (Government of Canada) Enhanced epidemiological summary Measles in Ontario (Public Health Ontario) Measles and rubella weekly monitoring report (Government of Canada) Enhanced epidemiological summary Measles in Ontario (Public Health Ontario) Measles exposures in Ontario (Public Health Ontario) Measles vaccine recommendations from NYP (jpg) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Raw cat food tests positive for H5N1 (CIDRAP) Influenza: Waste water scan for 11 pathogens WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Respiratory virus activity levels (CDC Respiratory Illnesses) FDA-CDC-DOD: 2025-2046 influenza vaccine composition (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Early impact of RSV vaccination in older adults in England (Lancet) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Evaluating the effectiveness of 2024-2025 seasonal mRNA-1273 vaccination against covid-19-associated hospitalizations and medically attended covid-19 among adults aged ≥ 18 years in the united states(medRxiv) Current Moderna vaccine 53% effective against COVID hospitalization?(CIDRAP) Preliminary estimates of COVID-19 burden for 2024-2025 (CDC COVID-19) Estimated range of annual burden of flu in the US from 2010 – 2024 (CDC-flu burden) US FDA missed the deadline for decision on Novavax's COVID-19 vaccine (Reuters) Interim clinical considerations for use of COVID-19 vaccines in the United States (CDC Vaccines & Immunizations) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Fusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Metformin alleviates inflammatory response and severity rate of COVID-19 infection in elderly individuals(Scientific Reports) Drug interaction checker (University of Liverpool) Infectious Disease Society guidelines for treatment and management (ID Society) Cost-effectiveness analysis of nirmatrelvir/ritonavir for high-risk individuals with COVID-19….does this mean use the big button calculator? (OFID) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC Managing healthcare staffing shortages (CDC) Steroids, dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reinfection with SARS-CoV-2 in the omicron era is associated with increased risk of post-acute sequelae of SARS-CoV-2  infection: a recover-EHR cohort study(medRxiv) CAN-PCC RecMap, your one-stop shop for recommendations about Post COVID-19 Condition (Long COVID) (Canadian Guidelines for post COVID-19 condition) Letters read on TWiV 1206 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Pharma industry tensions rise as Trump tariffs miss sector for now. FDA's interim CBER head appointed after key resignation. Xaira Therapeutics hires top AI academic. Novavax's COVID-19 shot review deadline missed by FDA. Trilink offers guide RNA for CRISPR workflow. Biotech sector sees investment surge. Beigene scraps candidate, Sarepta's gene therapy on hold in Europe. Biopharma professionals work long hours.In other news, there are safety concerns in Duchenne treatment. Democrats challenge Trump health cuts. And there are job opportunities in the biopharma industry.

Donald Trumps Zollpolitik belastet die Weltbörsen. Rüdiger und Robert analysieren die Lage.Erwähnte Titel: Microsoft, Deckers Outdoor, Cava Group, Moderna, Novavax, Biontech, Duolingo, Sea Limited, SentinelOne, Tesla, AT&S, OberbankAlle Folgen finden Sie auch auf KURIER.at und kronehit.at.Weitere Podcasts finden Sie unter KURIER.at/podcasts Hosted on Acast. See acast.com/privacy for more information.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Bristol Myers Squibb (BMS) has acquired 2seventy, the partner of Abecma, for $286 million, ending their cost-sharing agreement. Abecma generated $406 million in 2024, with BMS paying $43 million to 2seventy as part of their profit-sharing agreement.Beam Therapeutics has achieved genetic correction in AATD, while Viking secured a 1 billion supply of an obesity pill candidate. Novavax, Roche, and other companies are also making significant moves in the industry.The editorial reflects on the five years of COVID-19 and its ongoing impacts on the life sciences industry. Stay tuned for more updates on these developments and more in the world of Pharma and Biotech.

As we mark five years since the World Health Organization officially declared the COVID-19 pandemic, the BioSpace editorial team reflects on the health crisis of a generation and how it changed us—and the biopharma industry. While companies like Pfizer, BioNTech and Moderna raked in billions from their vaccines, J&J and Novavax struggled to capture a significant piece of the market.   Five years later, much has changed. A substantial number of us now work from the comfort of our homes—though that may be changing for some in the life sciences—and biopharma has a new obsession: obesity. In this space, Novo Nordisk has had a rough week, reporting lower-than-expected results from a second straight trial of its next-gen weight loss drug CagriSema. And in an effort to protect revenues from its blockbuster weight-loss drug Wegovy, Novo jumped into the legal battle between the FDA and compounding pharmacies over the regulator's decision to declare the shortage of Wegovy over. Viking Therapeutics had a better week, securing “multiple metric tons” of its investigational obesity medication VK2735 in a deal with CordenPharma. Meanwhile, companies continue to tackle adverse events associated with GLP-1s.  Another space that has seen its fair share of failures in the past couple of years is depression. The latest flop comes from J&J, which announced it would discontinue its a kappa opioid receptor blocker aticaprant after a disappointing Phase III readout. J&J joins Biogen and Sage Therapeutics, Relmada Therapeutics and Alto Neuroscience, all of whom have suffered regulatory misses or trial flops. Finally, two of Donald Trump's healthcare nominees, Marty Makary and Jay Bhattacharya, sailed through their confirmation hearings in the Senate last week. Both are up for confirmation on Thursday.   

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novo's next-generation weight loss drug, cagrisema, has disappointed once again with lower-than-expected weight loss results. The latest data showed only a 15.7% weight loss in patients with diabetes after 68 weeks, below the company's projections. This news has caused Novo's stock to dip. Additionally, side effects associated with GLP-1-based obesity drugs are turning patients away from this type of treatment. Despite efforts to mitigate these side effects, studies show that various factors are causing patients to discontinue treatment.In other news, Johnson & Johnson's oral IL-23R blocker has set a new standard in plaque psoriasis treatment, outperforming Bristol Myers Squibb's Sotyktu. BMS's Sotyktu did, however, notch a phase III win in psoriatic arthritis. Novo is also conducting studies on GLP-1s for addiction, limited to ongoing phase II trials. Overall, the landscape of weight loss and skin condition treatments is evolving, with new drugs showing promise and competition heating up in the market.Drugmakers are focusing on reducing the side effects of GLP-1-based obesity drugs to address high discontinuation rates among patients. Novavax is applying lessons learned from the COVID-19 pandemic as it looks towards developing other novel vaccines. The FDA faces a challenging decision on biomarker-based label restrictions for certain cancer drugs, while J&J has axed a late-stage depression trial due to underwhelming efficacy.Other news includes AstraZeneca's positive data on Imfinzi for stomach cancer and Takeda's drug reducing the need for blood withdrawals in clinical trials. Novavax is also working with pharma partners to bring new vaccines to market. The FDA is dealing with staff and site turnover, and more job opportunities in the biopharma industry are available.Readers are encouraged to provide feedback on what topics they would like to see covered in future articles.

Another video for this Sunday morning, based on the very popular New Year's How To Win piece. I hope you draw some inspiration from it. (I meant to put it out in Jan, but didn't).Please like, watch, share and all those other things.All the bestDominicPS Could I draw your attention to a couple of things…Lifetime Membership Many people do not know about this, so, for one week only, I am running promotion. For a one-off payment of just £450/$570 you will get full access to the Flying Frisby for life. Click the button below and you will see the option - I stress this is a one-off paymentPlease consider upgrading your subscription - and if one of last year's flyers - Lightbridge, Novavax or Microstrategy worked for you, then consider this a way of saying thank you!PPS As always, if buying gold to protect yourself in these uncertain times, I recommend The Pure Gold Company with whom I have an affiliation deal. Pricing is competitive, quality of service is high. They deliver to the UK, the US, Canada and Europe or you can store your gold with them. More here.PPPS This week's commentary about my recent experiences in the US and, in particular, Tesla, went down a storm. ICYMI here it is: This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.theflyingfrisby.com/subscribe

Eduardo Bolinches, analista de Invertia/El Español, analiza las acciones de Naturgy, Repsol, Novavax, eDreams o Aena, entre otras.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Lilly has stopped a mid-stage study on relaxin for chronic kidney disease due to a lack of foreseeable clinical benefit, following the drug's failure in a related heart failure study. Meanwhile, Novo Nordisk's Ozempic has received FDA approval for kidney disease, expanding its use beyond diabetes and weight loss. The FDA may see changes under RFK Jr. and Makary, with concerns raised about Kennedy's vaccine-related views. BioAge has dropped an obesity asset after going public, I-Mab and Zentalis are cutting staff, and Novavax is seeking silver linings two years into a reset. Stay tuned for more updates in the biotech industry.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Neurocrine has secured sole rights to a potentially first-in-class depression drug called Osavampator from Takeda. Little information has been released about the drug since its promising phase II performance last spring. Meanwhile, Novavax CEO John Jacobs discusses the company's progress after layoffs, pipeline reorganizations, FDA delays, and clinical holds. Additionally, Versant Ventures has launched a new obesity startup called Helicore with a focus on improving weight loss quality. Atai has reported positive data for psychedelic therapy in alcohol use disorder, following FDA approval of J&J's esketamine nasal spray for treatment-resistant depression. Other news includes AstraZeneca and Daiichi Sankyo expanding their ADC collaboration, Metsera seeking a $289 million IPO, Pfizer receiving a breather from Starboard's assault, and more updates in the biotech industry.

Plus: Shares of vaccine makers Moderna and Novavax rise after U.S. health officials confirmed the first American death caused by the H5N1 bird flu. Shares of Aurora Innovation, an Nvidia collaborator in self-driving trucks, climb 29%. J.R. Whalen reports. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ## Pfizer announces positive results for COVID-19 vaccinePfizer has announced positive results for its COVID-19 vaccine, with an efficacy rate of over 90%. This is a significant development in the fight against the pandemic, as it could potentially lead to widespread vaccination and a return to normalcy. ## Moderna receives FDA emergency use authorization for COVID-19 vaccineModerna has received emergency use authorization from the FDA for its COVID-19 vaccine. This is another important step in the fight against the pandemic, as it will allow for the vaccine to be distributed more widely and help to protect more people from the virus. ## Johnson & Johnson applies for emergency use authorization for COVID-19 vaccineJohnson & Johnson has applied for emergency use authorization from the FDA for its COVID-19 vaccine. If approved, this vaccine could provide another option for individuals looking to protect themselves from the virus. ## AstraZeneca faces scrutiny over COVID-19 vaccine dataAstraZeneca is facing scrutiny over the data from its COVID-19 vaccine trials. Questions have been raised about the efficacy of the vaccine, as well as potential safety concerns. This is a reminder of the importance of transparency and thorough evaluation in the development of vaccines. ## Novavax announces positive results for COVID-19 vaccineNovavax has announced positive results for its COVID-19 vaccine, with an efficacy rate of over 85%. This is another promising development in the fight against the pandemic, as it could provide yet another option for vaccination. ## ConclusionIn conclusion, there have been several significant developments in the world of COVID-19 vaccines. From positive results to emergency use authorizations, these updates are a testament to the hard work and dedication of researchers and scientists around the world. As we continue to navigate this challenging time, it is important to stay informed and vigilant in our efforts to combat the pandemic.

Every January, I like to make some predictions about the year ahead. Then, in my final post of the year, which this will probably be, I go back and review them. That's what we are doing today.Before I begin, just a couple of things:* In case you missed it, check out Friday's piece on North American tax loss selling. It has 9 ideas for short-term trades, which could come good by February.* And there is now a video version of "The Chainsaw and the Swamp: A Tale of Two Economies" for your Sunday morning viewing pleasure.Right. Here we go …Predictions are funny things. The more outlandish the prediction, the more entertaining the copy, but the less likely it is to actually happen. What is more important: getting lots of eyeballs or being right?I like this exercise because it demonstrates just how much perspective can change over time. While we can change strategy as events develop, what I wrote a year ago does not, so when you look back at stuff you got wrong, you can look foolish, even if you changed tack in real time. On the other hand, if you got stuff right, people go - well that was obvious.So the rules of my little game are this: I score two points for a direct hit, one for a good call, zero for a miss, and minus one for a "David Lammy on Mastermind" fail.I made 15 predictions. Here they are:1. The Great Decline goes on.I was pleased with this one, even if it was rather negative.“Everywhere the state's tentacles reach remains a drain on productivity. Our once-great institutions continue to fall apart, like zombie meth addicts, stumbling towards dysfunction... The ordinary worker desperately trying to improve his lot is bled dry by taxes, inflation, housing costs, and the voracious state monster. Fiat loses yet more of its purchasing power. The South Africanisation of everything continues.”Gosh, it's depressing and negative. Things may be changing on the other side of the pond, but they are not in Europe. Two points.2. Gold breaks out to new highs and goes to $2,400. And some. $2,790 was the high. We're now at $2,620. Two points.3. Bitcoin goes to new highs as well.Yup. We are at $98,000 as I write. $108,000 was the high. Two points.4. For reasons I don't understand, ethereum outperforms bitcoin.Ethereum always seems to move later in the cycle and by more, hence the prediction. But in 2024 bitcoin outperformed. Zero points.5. The US dollar trends sideways.It didn't. The US Dollar Index began the year at 100 and ended about 8% higher around 108. Another big fat zero.6. Sterling has problems.Cable began the year at around $1.27 and it's now at $1.25, having been as high as $1.34. So it's down a bit. But the eight-year cycle low that I am looking for has not materialized. I'm sure it's coming, but zero points.7. The Tories are eviscerated.Pleased with this one.They had their chance and they blew it. Come the General Election this year, the voters are unforgiving. … The SNP is similarly annihilated. The shortcomings of our political system are there for all to see. But nothing that needs to change does. Roughly 80% of the country did not vote Labour, yet they got 63% of the seats. Incredible. And they call it democracy. Two points.8. Uranium to hit $125/lb.Nope. The highest it got was $105/lb, and that was in January. It spent the rest of the year declining; it's now at $73. Minus one. Totally wrong.9. Fast and processed food companies have problems.I think I am early to this. Let's see what RFK does. But, by way of proxy, McDonald's is flat on the year; Burger King (Restaurant Brands International) is down 14%; KFC is off about 10%.Good call. Two points.Seed oils are losing.10. Good year for the Japanese yen. It has to go up sometime right? It's so cheap.Nope. It went down. Minus one.11. The S&P500 has a good year.I'll say. It's up 25%. Way above expectation. Two points.12. Small caps outperform.Apart from a brief spell in summer, they didn't. It feels like they are starting to, but nope. Zero points.13. UK house prices. Atrophy and stagnation, but no meltdownThat feels about right. About 50% of stuff on the market isn't selling, apparently. I'm not surprised; the cost of moving is so high. Two points.14. Silver. Can it stage a meaningful rally above $30?Nope, I said. It went to $34 in October. Now it's $29. Was that rally meaningful? Well, it did better than I thought it would. Zero points.15. Liverpool win the league; Sheffield United, Burnley, and Luton are relegated.Got the losers right but not the winners. 1 point.All in all, not a great showing. 13 points.Oddly enough, whenever I score low on the predictions, I have a much better year in the portfolio. That was the case this year, where we have had some real winners in the Flying Frisby: bitcoin and MicroStrategy, obviously, but also Lightbridge and Novavax too. Meanwhile, the low-risk Dolce Far Niente portfolio is rocking it.Happy Christmas everyone. Thank you for being a subscriber.And why not gift someone a subscription this Christmas?I'll have some predictions for 2025 early in the new year.Until next time.DominicPS Don't forget:* In case you missed it, Friday's piece on North American tax loss selling has 9 ideas for short-term trades, which could come good by February.* Plus the video version of "The Chainsaw and the Swamp: A Tale of Two Economies" for your Sunday morning viewing pleasure.Become enlightened. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.theflyingfrisby.com/subscribe

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Pfizer announces new vaccine distribution planPfizer has announced a new vaccine distribution plan that aims to reach more people in rural areas. The company will be partnering with local health departments and community organizations to set up vaccination sites in underserved areas. This move comes as the demand for vaccines continues to increase across the country. ## Moderna reports positive results from Phase 3 trialModerna has reported positive results from its Phase 3 trial of the COVID-19 vaccine. The company says that the vaccine was highly effective at preventing symptomatic cases of the virus. This news comes as a welcome development in the fight against the pandemic, as Moderna works to ramp up production and distribution of its vaccine.## Johnson & Johnson seeks emergency use authorization for single-dose vaccineJohnson & Johnson has submitted an application for emergency use authorization for its single-dose COVID-19 vaccine. The vaccine was shown to be safe and effective in clinical trials, and could provide a much-needed boost to vaccination efforts. If approved, the Johnson & Johnson vaccine would be the third vaccine available in the United States.## AstraZeneca faces manufacturing challengesAstraZeneca is facing manufacturing challenges that could impact its ability to deliver vaccines on time. The company has fallen behind on production targets, leading to delays in shipments to several countries. AstraZeneca says it is working to resolve the issues and increase production in order to meet demand.## Novavax announces progress on vaccine developmentNovavax has announced progress on its COVID-19 vaccine development program. The company says that its vaccine candidate showed strong efficacy in clinical trials, with promising results in preventing infection. Novavax is now working to secure regulatory approval for its vaccine and ramp up production to meet global demand.## ConclusionIn conclusion, the pharmaceutical industry continues to make strides in the fight against COVID-19. With new vaccines being developed and distributed, there is hope on the horizon for controlling the spread of the virus. Stay tuned for more updates on these developments and more in the world of Pharma and Biotech.

Hi there! Today, travel medicine specialists Drs. Paul Pottinger ("Germ") & Chris Sanford ("Worm") answer your travel health questions:What's happening with Marburg disease in Rwanda?Are rabies vaccinations important?What gift(s) should I bring when visiting a new country?Japanese encephalitis vaccination: Necessary if visiting Sri Lanka, Turkey, and India?What's the deal with West Nile Virus infection?What infectious diseases are likely to spread after a disaster?What's the deal with Novavax halting its clinical trial of the combined COVID / Flu vaccine?We hope you enjoy this podcast! If so, please follow us on the socials @germ.and.worm, subscribe to our RSS feed and share with your friends! We would so appreciate your rating and review to help us grow our audience. And, please send us your questions and travel health anecdotes: germandworm@gmail.com.Our Disclaimer: The Germ and Worm Podcast is designed to inform, inspire, and entertain. However, this podcast does NOT establish a doctor-patient relationship, and it should NOT replace your conversation with a qualified healthcare professional. Please see one before your next adventure. The opinions in this podcast are Dr. Sanford's & Dr. Pottinger's alone, and do not necessarily represent the opinions of the University of Washington or UW Medicine.

In his weekly clinical update, Dr. Griffin apprises us about the first case of highly pathogenic influenza in Canda, children dying of influenza infection and novel genetic reassortments of the virus, the Marburg virus outbreak in Rwanda, number of mpox infections, before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, how scientific mistrust has affected COVID-19 vaccine administration, resolution of the FDA hold on Novovax's combination influenza and COVID vaccine, where to find PEMGARDA, how Paxlovid SAVES you money, when to use steroids to treat COVID-19 and how trace amounts of cytokines elicted during SARS-CoV-2 infection negatively impact cardiac function. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Bird flu flew into British Columbia Canada (Global News Canada) H5N1 in British Columbia (CIDRAP) Highly Pathogenic Avian Influenza flies commercial and domestic (USDA) Countdown till the end of Marburg outbreak (WHO Rwanda) First kid's death due to flu (CIDRAP) Influenza weekly surveillance report: clift notes (CDC FluView) H5N1 novel reassortments in migratory birds in China (Emerging Infectious Diseases) Serologic evidence of recent infection with highly pathogenic avian influenza A (MMWR) Seriously? 50,000 mpox cases in African outbreak (CIDRAP) Respiratory virus activity (CDC Respiratory Illnesses) COVID-19 deaths (CDC) COVID-19 national and regional trends (CDC) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Science trust: behind COVID 19 vaccine acceptance (Vaccine X) Vaccine mistrust levels are not budging (Healthday) FDA clinical hold lifted on Novavax's combination COVID-flu vaccine(Reuters) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Fusion center near you….if in NY (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Infectious Disease Society guidelines for treatment and management (ID Society) Drug interaction checker (University of Liverpool) Real-world effectiveness of nirmatrelvir-ritonavir and molnupiravir  (CMI: Clinical Microbiology and Infection) Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (CID) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC) Managing healthcare staffing shortages (CDC) Steroids, dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Secondary bacterial infection follows COVID-19 (Nature Communications) Daniel Griffin's evidence based medical practices for long COVID (OFID) Post-acute sequelae of SARS-CoV-2 cardiovascular symptoms are associated with trace-level cytokines that affect cardiomyocyte function (Nature Medicine) Letters read on TWiV 1166 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.AbbVie's shares dropped by 12% after its schizophrenia drug, emraclidine, failed in a phase II trial. This failure has raised concerns about the company's long-term neuroscience strategy. In the Huntington's disease space, companies like Prilenia and Wave Life Sciences are working on potential disease-modifying treatments, offering hope for a community that has faced disappointment in recent years. Rapt Therapeutics has crashed after liver injury concerns with its drug, and AstraZeneca and Amgen claim a late-stage win in chronic rhinosinusitis. The FDA has lifted a clinical hold on Novavax's COVID/flu vaccine candidates, while GSK has left the trade group BIO. Overall, the pharmaceutical industry is facing challenges and uncertainties as it continues to develop new treatments for various diseases.

In March 2020, we launched our first podcast on COVID-19. Over the past four years, we've seen many changes—some positive, some negative. While many of us are eager to move past COVID (myself included), it's clear that COVID is here to stay. This week, we sit down with infectious disease experts Peter Chin-Hong and Lona Mody to discuss living with COVID-19. Our conversation covers: The current state of COVID Evidence for COVID boosters, who should get them, and preferences between Novavax and mRNA vaccines COVID treatments like Molnupiravir and Paxlovid Differences in COVID impact on nursing home residents and those with serious illnesses We wrap up with a “magic wand” question. My wish was for better randomized evidence for vaccines and treatments, though I worry this might not be feasible. In the meantime, there's significant room to improve vaccine uptake among high-risk groups, particularly nursing home residents. Currently, only 1 in 5 nursing home residents in the US have received the COVID booster, compared to over 50% in the UK. By: Eric Widera  

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über das wilde US-Earnings-Bonanza, einen Milliardendeal bei Siemens und vier Horrorfaktoren, die Anleger das Fürchten lehren. Außerdem geht es um VW, DHL, BASF, Meta, Microsoft, Google, Snap, Booking, Coinbase, Robinhood, Starbucks, Nvidia, Moncler, Hims&Hers, Pernod Ricard, Eli Lilly, Pernod Ricard, Remy Cointreau, Diageo, Roku, Reddit, Robinhood, Airbus, Starbucks, Grenke, Hims&Hers Health, Apple, State Street, Regeneron, HypoReal Estate, Wirecard, Riot Platforms, National Bank of Greece, Eurobank Ergasias, ABB, Ahold, Energiekontor, Encavis, Social Chain, Varta, HeidelbergPharma, Novavax, Microstrategy und Intershop. Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Episode: Leading the Way Through Respiratory Virus Season Host: Ghinwa Dumyati, MD, Professor of Medicine, Director of the Communicable Diseases Surveillance and Prevention Program, University of Rochester Guest(s): Kelly Langford, Online Communications Director for the Risk Less. Do More. Campaign, U.S. Department of Health and Human Services In This Episode: In this episode of PALTtalk, Dr. Ghinwa Dumyati and Kelly Langford discuss the importance of immunizations during respiratory virus season, focusing on flu, COVID-19, and RSV. They highlight the new Risk Less. Do More. campaign, which aims to reduce infection risks, especially among vulnerable populations, including older adults in long-term care facilities. Since the recording of this episode, the Advisory Committee on Immunization Practices (ACIP) released updated COVID-19 vaccination guidance for 2024-2025. In addition to the previously recommended 2024-2025 COVID-19 vaccination, ACIP now recommends a second dose of the 2024-2025 COVID-19 vaccine for adults ages 65 and older. For those who are previously unvaccinated and receiving Novavax, two doses are recommended as the initial vaccination series. This should be followed by a third dose of any age-appropriate 2024-2025 COVID-19 vaccine at least 6 months after the second dose, with a minimum interval of 2 months. Date Recorded: October 22, 2024 Resources: Risk Less. Do More. Campaign (HHS) Moving Needles Project (PALTmed and CDC) Talking with Patients About Respiratory Virus Season (CDC) Available Credit: The American Board of Post-Acute and Long-Term Care Medicine (ABPLM) issues CMD credits for select PALTtalk podcast episodes as follows: This episode is certified for CMD Clinical hours. Claim CMD Credit Support: Funding for this podcast was provided through the Risk Less. Do More. campaign from the U.S. Department of Health and Human Services.

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:   The good — FDA approves AbbVie 24-hour Parkinson's treatment  The bad — Sage Therapeutics axes workforce  The ugly — FDA halts Novavax's COVID-flu vaccine trials 

UnitedHealth Group's stock tumbles as it reveals a jump in medical costs hurt its 2025 profit outlook. More than 1,500 physicians call on the Trump campaign to release an outline of healthcare plans after the former-president said he wants to replace the Affordable Care Act. And, the Food and Drug Administration halts the clinical application of Novavax's combination COVID-influenza shot, following a report of a significant reaction from a trial participant. We'll get that story—and more—coming up on today's episode of the Gist Healthcare podcast. Hosted on Acast. See acast.com/privacy for more information.

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Laurin Meyer und Philipp Vetter über Übernahmephantasie bei Nagarro, ein fettes Minus für Adidas trotz guter Zahlen und schlechte Nachrichten für Novavax. Außerdem geht es um Puma, Sartorius, Tecan, Morgan Stanley, U.S. Bancorp, Amazon, Alphabet, Microsoft, Meta, Oklo, Nuscale Power, Uranium Energy, BWX Technologies, Centrus Energy, VanEck Uranium and Nuclear Technologies UCITS ETF (WKN: A3D47K) und Global X Uranium UCITS ETF (WKN: A3DC8S). Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Unser Partner Scalable Capital ist der einzige Broker, den du brauchst. Inklusive Trading-Flatrate, Zinsen und Portfolio-Analysen. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Feierlaune in DE: Roßman investiert massiv in Aurubis. SAP überholt ASML. Nagarro hat Übernahme-Gerüchte. Feierlaune in US: Bei Morgan Stanley ist IB noch möglich und United Airlines hebt die Preise an. Nicht so gut: Novavax leidet.Lovisa (WKN: A12G1C) verkauft billigen Schmuck. Lovisa hat aber auch 90% Rendite in zwölf Monaten, eine Bruttomarge von 80% und enormes Wachstum. Unbegrenzte Kredite ohne Sicherheiten. Dezentrales Traden. Auf 1.000 verschiedenen Wegen Staking betreiben. Aave, Compound, viele Swaps, LIDO und Eigenlayer machen's möglich. Diesen Podcast vom 17.10.2024, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA has paused Novavax's investigational flu and COVID-flu vaccines due to a serious adverse event of motor neuropathy. This affects their COVID-flu combo and standalone flu vaccines, which were about to enter phase III testing. Meanwhile, Takeda has decided to terminate its partnership with Wave on a Huntington's disease program after investing $260 million. Novavax shares have slid due to the FDA pause, while GSK is suing Moderna for patent infringement on COVID-19 and RSV vaccines. Sanofi is also preparing to sell its consumer healthcare business.Artificial intelligence (AI) is playing a significant role in accelerating innovation in biopharma, particularly in drug development. While AI is infiltrating various stages of the process, it is not replacing human input entirely. One example of AI's impact is seen in Regeneron and Sanofi's Dupixent, which is expected to dominate the COPD biologics market with predicted revenues exceeding $6.5 billion within a decade. Additionally, Sanofi's move to sell its consumer healthcare business follows a trend among big pharma companies offloading such divisions.In the realm of biologics discovery, harnessing the power of AI and patent data can revolutionize the industry. Despite challenges related to limited access to high-quality, fair-compliant data, leveraging patent information can fill this gap and drive innovation in drug development. Takeda has walked away from its partnership with Wave Huntington after investing $260 million in the collaboration. J&J has announced Q3 earnings, including scrapping pipeline assets and raising full-year guidance. Novo's $16.5 billion buyout of Catalent faces scrutiny amid an FTC review, while GSK has sued Moderna for alleged patent infringement.Overall, the biopharma industry continues to evolve with the integration of AI, strategic partnerships, regulatory changes, and financial developments shaping its landscape.

Comprehensive coverage of the day's news with a focus on war and peace; social, environmental and economic justice. Former President Donald Trump on Friday said he will vote no on a Florida ballot measure that would repeal the state's six-week abortion ban, a day after he seemed to indicate he would vote in favor of the measure. U.S. regulators approve Novavax's updated COVID-19 vaccine for fall. California nears ban on plastic bags at checkout with two bipartisan bills. Clean energy advocates and state lawmakers gathered at a hydrogen fueling station near the Port of Oakland today to celebrate a $1.2 billion deal to create a statewide clean hydrogen hub. Officials at the Oakland Unified School District were under fire this week as they apologized for the district's delay in informing school communities about elevated lead levels in the water at dozens of schools. The post Trump reverses position, says he will vote against Florida measure repealing six-week abortion ban – August 30, 2024 appeared first on KPFA.

AP correspondent Haya Panjwani reports on a newly approved COVID-19 vaccine in the U.S.

(2:00) NewsPhil Donahue dies — remember when the radical left was anti-war instead of totalitarian warmongers?  Donahue was fired for opposition to Iraq warAyn Rand tells Donahue why she thought selfishness was a virtueFamilies are now so dysfunctional that they need a charity to help potty train their kidsGPS and the fragile infrastructure that's turning people into the Eloi of HG Well's Time Machine(34:16) Live and Let DEI — Secret Service literally asleep and another "chestfeeding" a baby while on duty (37:31) D&C ConventionWATCH Biden gets mixed up about women and power — taking electrical power away is good but he gets it mixed up with electoral powerSay Commie-La or you're racist - mispronouncing her name is unconscious bias at the very least, we're toldHow they got rid of Biden so easily.  Will they remove him from the presidency?The Democrat Cult of Death — never before has a party been so focused on openly celebrating murderLala has vax mandate for all campaign workers.  Your body, your choice? Freedom?CDC recommends Pfizer, Moderna & Novavax.  Peter McCullough also recommends Novavax and Molnupiravir which has EUA, Emergency Use Authorization.  What emergency?(1:06:21) Thanks to the producers that make the show possible (1:07:12) More D&C…Mao's WalzDemocrats DOUBLE DOWN on Walz's false military rankMore troubling details about Walz's fascination with Mao & Communist China.  The kindly uncle that's really the Manchurian Candidate.  What's not to love about the one-child policy?Trump's criticism of Lala's "economic" program is shallow and hypocritical.  It's actually the Washington Post that nailed her!"Sleeping" her way to the top(1:30:54) Woman arrested multiple times for silent prayer near sacred abortion space wins big payout….so the Thought Police move to make silent prayer illegal (1:37:33) "Church of England" moves to drop "church" from its name!  Not evolving but dissolving (1:40:42) Americans who identify as Christians has dropped from 90% in the 90's to 63%.  What demographic is leaving the fastest? (1:45:17) Bipartisan embrace of abortion from Austin ($500,000 for "abortion transportation") to NY (1:53:47) Cuba Shows How Cars Will Finally Be Ended Is THIS how cars ownership will be ended?  Communism and subsequent poverty ended Cubans being able to purchase cars.  But they managed to keep what they had running for the last 60 years…until now. (2:03:12) Eric Schmidt, Former Google CEO: Steal, Then Hire Lawyers Move fast and steal things.  Schmidt still has tremendous influence in Military Industrial Complex and with Democrats' White House.  He's now trying to walk back what he said at Stanford (2:14:07) BREAKING NEWS Prior Restraint of Ballot Access as Trump & Lala File Lawsuits Election corruption begins with ballot access and the two party system has mastered the manipulation.  Lala sues in NJ and Trump in WI to keep Dr. Shiva off the ballot. Dr. Shiva, shiva4president.com,  joins to give his perspective on citizenship, loyalty to THIS country over other countries, and the role of electors.Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Money should have intrinsic value AND transactional privacy: Go to DavidKnight.gold for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to TrendsJournal.com and enter the code KNIGHTBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

(2:00) NewsPhil Donahue dies — remember when the radical left was anti-war instead of totalitarian warmongers?  Donahue was fired for opposition to Iraq warAyn Rand tells Donahue why she thought selfishness was a virtueFamilies are now so dysfunctional that they need a charity to help potty train their kidsGPS and the fragile infrastructure that's turning people into the Eloi of HG Well's Time Machine(34:16) Live and Let DEI — Secret Service literally asleep and another "chestfeeding" a baby while on duty (37:31) D&C ConventionWATCH Biden gets mixed up about women and power — taking electrical power away is good but he gets it mixed up with electoral powerSay Commie-La or you're racist - mispronouncing her name is unconscious bias at the very least, we're toldHow they got rid of Biden so easily.  Will they remove him from the presidency?The Democrat Cult of Death — never before has a party been so focused on openly celebrating murderLala has vax mandate for all campaign workers.  Your body, your choice? Freedom?CDC recommends Pfizer, Moderna & Novavax.  Peter McCullough also recommends Novavax and Molnupiravir which has EUA, Emergency Use Authorization.  What emergency?(1:06:21) Thanks to the producers that make the show possible (1:07:12) More D&C…Mao's WalzDemocrats DOUBLE DOWN on Walz's false military rankMore troubling details about Walz's fascination with Mao & Communist China.  The kindly uncle that's really the Manchurian Candidate.  What's not to love about the one-child policy?Trump's criticism of Lala's "economic" program is shallow and hypocritical.  It's actually the Washington Post that nailed her!"Sleeping" her way to the top(1:30:54) Woman arrested multiple times for silent prayer near sacred abortion space wins big payout….so the Thought Police move to make silent prayer illegal (1:37:33) "Church of England" moves to drop "church" from its name!  Not evolving but dissolving (1:40:42) Americans who identify as Christians has dropped from 90% in the 90's to 63%.  What demographic is leaving the fastest? (1:45:17) Bipartisan embrace of abortion from Austin ($500,000 for "abortion transportation") to NY (1:53:47) Cuba Shows How Cars Will Finally Be Ended Is THIS how cars ownership will be ended?  Communism and subsequent poverty ended Cubans being able to purchase cars.  But they managed to keep what they had running for the last 60 years…until now. (2:03:12) Eric Schmidt, Former Google CEO: Steal, Then Hire Lawyers Move fast and steal things.  Schmidt still has tremendous influence in Military Industrial Complex and with Democrats' White House.  He's now trying to walk back what he said at Stanford (2:14:07) BREAKING NEWS Prior Restraint of Ballot Access as Trump & Lala File Lawsuits Election corruption begins with ballot access and the two party system has mastered the manipulation.  Lala sues in NJ and Trump in WI to keep Dr. Shiva off the ballot. Dr. Shiva, shiva4president.com,  joins to give his perspective on citizenship, loyalty to THIS country over other countries, and the role of electors.Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Money should have intrinsic value AND transactional privacy: Go to DavidKnight.gold for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to TrendsJournal.com and enter the code KNIGHTBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.